Mauna Kea Technologies announces entrance into exclusive negotiations
for a licensing agreement for Cellvizio® in an important therapeutic area
with a major industry player

The Company also confirms that it is pursuing licensing discussions in other therapeutic
areas

The protective framework of the safeguard proceedings enables Mauna Kea Technologies
to intensify discussions on financing options with long-term investors



Paris and Boston, April 01, 2025 – 8:50 a.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT),
inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE)
platform, today announces entering into exclusive negotiations for a licensing agreement for its Cellvizio
technology in an important therapeutic area with a major industry player.

As part of its strategic process launched a few months ago, the Company is also pursuing several licensing
discussions covering other therapeutic areas, reflecting a growing interest in the Cellvizio technology across
multiple medical specialties.

In parallel, and following the opening of the safeguard procedure announced on March 31, 2025, the Company
intends to intensify its discussions regarding financing options with long-term investors in order to consolidate
its financial position and support its future growth.

“This exclusive negotiation agreement is a concrete example of the implementation of our strategy to monetize
technological assets, and demonstrates the growing attractiveness of our Cellvizio platform to major players
in the industry,” said Sacha Loiseau, Chairman and CEO of Mauna Kea Technologies. “The safeguard
proceedings now provide us with a structured framework to accelerate this strategy and enter into long-term
discussions with industry and financial partners.”

***

About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo
cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to
monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify
indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide
range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For
more information, visit www.maunakeatech.com.


Mauna Kea Technologies NewCap - Investor Relations
investors@maunakeatech.com Aurélie Manavarere / Thomas Grojean
+33 (0)1 44 71 94 94
maunakea@newcap.eu

1
Disclaimer
This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than
statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies'
financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea
Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be
given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are
subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2023 Annual Report
filed with the Autorité des marchés financiers (AMF) on April 30, 2024, which is available on the Company's website
(www.maunakeatech.fr), as well as the risks associated with changes in economic conditions, financial markets and the markets in
which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that
are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of
some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies
to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein
do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea
Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law.
Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.




2